🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/02/2013 27,43 28,10 27,00 27,47 -0,51% 4,01% 951.800
19/02/2013 26,44 27,74 26,32 27,61 +4,98% 5,37% 1.128.300
15/02/2013 26,23 27,08 25,80 26,30 +0,65% 4,88% 927.800
14/02/2013 26,28 27,23 25,86 26,13 -2,72% 5,21% 1.233.800
13/02/2013 27,16 27,35 26,50 26,86 -0,74% 3,13% 705.300
12/02/2013 27,66 27,75 26,84 27,06 -1,42% 3,29% 751.400
11/02/2013 27,94 28,60 27,11 27,45 -5,05% 5,33% 1.740.000
08/02/2013 28,20 29,15 27,89 28,91 +3,10% 4,47% 1.055.700
07/02/2013 27,81 28,70 27,34 28,04 -0,04% 4,89% 1.177.200
06/02/2013 27,78 28,25 27,57 28,05 +0,61% 2,45% 614.900
05/02/2013 27,56 28,09 27,20 27,88 +1,34% 3,23% 492.100
04/02/2013 27,46 28,50 27,09 27,51 -0,33% 5,13% 642.200
01/02/2013 27,42 28,35 27,13 27,60 +2,03% 4,45% 831.500
31/01/2013 27,36 27,61 26,10 27,05 -0,33% 5,52% 838.100
30/01/2013 26,93 29,30 24,50 27,14 -0,15% 17,82% 3.718.800
29/01/2013 27,06 27,43 26,66 27,18 -0,62% 2,85% 575.200
28/01/2013 28,03 28,25 26,80 27,35 -2,01% 5,17% 1.281.200
25/01/2013 25,56 28,00 25,18 27,91 +14,43% 11,03% 2.351.300
24/01/2013 24,41 25,64 24,25 24,39 -1,18% 5,69% 907.600
23/01/2013 24,48 24,85 24,26 24,68 +1,36% 2,41% 692.400
22/01/2013 24,18 24,44 23,46 24,35 +1,59% 4,05% 802.400
18/01/2013 23,99 24,58 23,85 23,97 -0,21% 3,04% 802.700
17/01/2013 24,85 25,60 23,88 24,02 -2,75% 6,92% 1.612.300
16/01/2013 25,25 25,59 24,55 24,70 -3,02% 4,12% 1.076.700
15/01/2013 25,00 26,13 24,70 25,47 +0,99% 5,72% 658.400
14/01/2013 25,94 26,50 25,10 25,22 -3,67% 5,40% 802.300
11/01/2013 26,41 26,50 24,80 26,18 -0,04% 6,44% 1.400.000
10/01/2013 27,71 27,90 25,86 26,19 -3,22% 7,36% 1.212.100
09/01/2013 28,57 28,79 26,94 27,06 -4,31% 6,48% 1.445.800
08/01/2013 29,24 29,49 27,55 28,28 -2,31% 6,63% 1.046.800